Medical Research

Discovery may be key to Alzheimer's treatment

March 20, 2014
Bloomberg News
Scientists have discovered that a gene-regulating protein that protects the developing brain of a fetus resurfaces in old age and may stave off dementia, a finding that could open a new path in Alzheimer’s research.
More

Deals up, dollars down in 2013 for Indiana life sciences firms

February 10, 2014
J.K. Wall
Venture capitalists and angel investors put a combined $31.9 million into 18 life sciences companies last year, with some of the largest amounts going to Nextremity Solutions, hc1.com and FAST BioMedical.
More

Three groups puzzled by woman's $7 million bequest

January 8, 2014
Associated Press
The organizations which include Indianapolis-based Hoosier Oncology Group have no idea why an Evansville teacher chose them as beneficiaries.
More

Lilly invests in NY life sciences venture capital initiative

December 4, 2013
 IBJ Staff
Indianapolis-based Eli Lilly and Co. has joined two other companies to contribute $40 million to an early-stage life sciences venture capital initiative in New York City.
More

Purdue makes big push into state's pharma industry

November 2, 2013
J.K. Wall
With a $60 million-plus investment, the university aims to take molecules from discovery to clinical trials.
More

VC headwinds continue for life sciences firms

October 21, 2013
J.K. Wall
Indiana life sciences companies trying to raise venture capital continue to do so with a national wind in their faces, according to the third-quarter venture capital data.
More

IU med school's research efforts have multiplied, but so have peers'Restricted Content

July 27, 2013
J.K. Wall
Retiring Indiana University School of Medicine Dean Dr. Craig Brater has, in his 13-year tenure, doubled the school's number of research-oriented faculty to 700, doubled the amount of space for them to work in, and doubled the revenue from research grants and contracts. But all that effort has hardly budged IU in national rankings.
More

Lilly aims potential Alzheimer’s drug at early patients

July 12, 2013
Bloomberg News
The trial of 2,100 patients, called Expedition III, will use new measures of cognitive function, such as the ability to do tasks like cooking or driving, or remembering words after a delay.
More

Lilly drug for Alzheimer's gets limited Medicare coverage

July 8, 2013
Bloomberg News, Associated Press
Lilly officials said they will push ahead with the first-of-a-kind imaging chemical, despite the mostly negative ruling by Medicare officials.
More

Lilly to take over development of diabetes drug

June 17, 2013
Associated Press
Eli Lilly and Co. will pay Canadian drug developer Transition Therapeutics Inc. at least $7 million and up to as much as $247 million to take over the development of a potential diabetes treatment.
More

Lilly's Alzheimer’s effort may gain from brain-mapping plan

February 18, 2013
Bloomberg News
Roche AG and Eli Lilly and Co., two drugmakers racing to develop treatments for some of the least understood brain disorders, may gain the most from a U.S. government boost in funding to fully map the human brain.
More

Indy loses promising health startup

November 12, 2012
J.K. Wall
LabDoor, which soon will launch an iPhone app that assigns A-F grades to over-the-counter vitamins and medicines, moved last month from Indianapolis to San Francisco, where it received $100,000 in startup financing.
More

Lilly CEO calls for life sciences research institute

October 23, 2012
J.K. Wall
Eli Lilly CEO John Lechleiter on Tuesday called for creation of a "world-class" research institute in Indianapolis to bring together scientists from universities and corporations to develop new medical therapies and companies.
More

Alzheimer’s prevention seen promising as drug cures fail

October 19, 2012
Bloomberg News
Researchers are set to test drugs by Eli Lilly and other companies that may prevent Alzheimer’s disease after efforts to find a cure have been unsuccessful.
More

Sledge's exit will keep IU program mostly intact

October 1, 2012
J.K. Wall
The departure of Dr. George Sledge likely will sap the breast cancer research program at the Indiana University Melvin and Bren Simon Cancer Center of about $500,000 in annual funding. But the program Sledge built over the past three decades mostly will remain intact.
More

Purdue health care engineering center lands another $10M

September 12, 2012
J.K. Wall
Purdue University’s Regenstrief Center for Healthcare Engineering will get another $10 million from the Indianapolis-based Regenstrief Foundation, keeping its research going through 2018.
More

Alzheimer's quest puts Lilly to test

August 11, 2012
J.K. Wall
Odds are long that Eli Lilly and Co.'s leading Alzheimer's drug will show positive results when its Phase 3 trial results are released within a few weeks, but even the smallest improvement in the cognitive impairment of test patients would be a home run for Lilly.
More

Despite funding dip, IU bets on brains

August 6, 2012
J.K. Wall
The city that brought the world Prozac and other neuroscience drugs is doubling down on brain research with a new $52 million research center near Methodist Hospital.
More

Indiana Blood Center tapping new vein of revenueRestricted Content

July 28, 2012
Mason King
Group sees role in cellular therapy as growth area with profit margins higher than core business.
More

IU research leads to new genetic test

June 4, 2012
J.K. Wall

It took the identification of 19 different genes for researchers at the Indiana University School of Medicine to develop a test for a rare form of cancer. But their gene-hunting has paid off, as a Texas-based company announced Monday the test is available for doctors to use.

More

NFP of NOTE: Cornea Research Foundation of AmericaRestricted Content

May 19, 2012
The Cornea Research Foundation of America is a not-for-profit clinical research organization dedicated to the preservation and restoration of vision.
More

U.S. losing drug-research jobs to other countries

May 17, 2012
Bloomberg News
Eli Lilly and other big pharmaceutical companies are creating thousands of research jobs overseas as countries led by Singapore, Ireland and South Africa boost incentives.
More

BioCrossroads has stoked state's life sciences industry, but challenges remainRestricted Content

February 11, 2012
J.K. Wall
In the 10 years BioCrossroads has been promoting life sciences in Indiana, the effort has netted more than 330 new companies, an infusion of more than $330 million in venture capital, a tripling of exports, and a growing number of mentions in national reports on life sciences.
More

Q&A

December 27, 2011
J.K. Wall

Dr. Bryan Schneider, a professor at the Indiana University School of Medicine, led a team of researchers in identifying genetic variations that dispose some breast cancer patients to neuropathy when they are receiving chemotherapy with the drug Taxol. Schneider’s research was named one of the biggest advances in cancer research this year by the American Society of Clinical Oncology. The society’s foundation also gave Schneider a three-year, $450,000 grant to further the research.

More

IU med school gets $9M for Alzheimer's center

November 1, 2011
J.K. Wall
The grant is the fifth consecutive five-year grant the Alzheimer Disease Center has received from NIH to support research to understand the causes and potential treatments for Alzheimer’s and other forms of dementia.
More
Page  1 2 3 4 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. OK Larry, let's sign Lance, shore up the PG and let's get to the finals.

  2. A couple of issues need some clarification especially since my name was on the list. I am not sure how this information was obtained and from where. For me, the amount was incorrect to begin with and the money does not come to me personally. I am guessing that the names listed are the Principal Investigators (individual responsible for the conduct of the trail) for the different pharmaceutical trials and not the entity which receives the checks. In my case, I participate in Phase II and Phase III trials which are required for new drug development. Your article should differentiate the amount of money received for consulting, for speaking fees, and for conduct of a clinical trial for new drug development. The lumping of all of these categories may give the reader a false impression of physicians just trying to get rich. The Sunshine Law may help to differentiate these categories in the future. The public should be aware that the Clinical Trial Industry could be a real economic driver for Indiana since these revenues supports jobs and new job creation. Nationally, this account for 10-20 billion which our State is missing out on to a large degree. Yes, new drug and technology development has gotten most of the attention (e.g. CTSI, BioCrossroads, etc.) However, serious money is being left on the table by not participating in the clinical trials to get those new drugs and medical devices on the market!!!! I guess that this is not sexy enough for academia.

  3. The address given for the Goldfish Swim Club is the Ace Hardware, is it closing?

  4. Out of state management and ownership. If Kite controlled it, everything would be leased. Of course, due to the roundabout, there is limited access to the south side of 116th now also. Just have to go down to the light.

  5. Hey smudge, You're opposed to arresting people for minor crimes? Sounds great! We should only focus on murders and such, right? Let's stand around and wait until someone shoots someone before we act. Whatever we do, we should never question anyone, frisk anyone, or arrest anyone unless they are actively engaged in shooting or stabbing. Very sound!

ADVERTISEMENT